Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Tracks memory and thinking after brain radiation for blood cancers

Studies memory and thinking in people with blood cancers after brain radiation.

Plain-language title generated from the registry record
Registry title: Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Key facts

Where
Houston, United StatesSee the site

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
M.D. Anderson Cancer Center
Trial code
NCT05011045
Record updated
20 May 2026
Original description
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.Read full original descriptionShow less

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Inclusion: Age 18 years or older; Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma [PCNSL], secondary central nervous system lymphoma [SCNSL], leukemia, myeloma); Proficient and capable of completing tests in English; Patients with claustrophobia are eligible if the claustrophobia is managed with medication; Patients with cognitively-impairment are eligible if the impairment is managed with medication; Patients who are pregnant.

ClinicalTrials.gov NCT05011045